|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||
  British Journal of DermatologyVolume 154 Issue 5, Pages 977 - 978 Published Online: 22 Feb 2006 Journal compilation © 2010 British Association of Dermatologists An Official Journal of the British Association of Dermatologists
Abstract | References | Full Text: HTML, PDF (Size: 47K) | Related Articles | Citation Tracking  CONCISE COMMUNICATION Clindamycin and rifampicin combination therapy for hidradenitis suppurativa Copyright 2006 British Association of Dermatologists KEYWORDS clindamycin • combination therapy • hidradenitis suppurativa • rifampicin ABSTRACTBackground Hidradenitis suppurativa (HS) is a chronic inflammatory condition affecting apocrine gland-bearing areas of the skin. There is currently no satisfactory treatment. Objectives To assess the efficacy of a 10-week course of combination clindamycin 300 mg twice daily and rifampicin 300 mg twice daily in the treatment of HS. Methods Patients who had received combination therapy with clindamycin and rifampicin for HS at one U.K. Dermatology Centre between the years 1998 and 2003 were identified from pharmacy records. Their records were analysed retrospectively. Results Fourteen patients with HS had received treatment with combination therapy. Eight of these patients achieved remission and a further two achieved remission when minocycline was substituted for clindamycin. Four patients were unable to tolerate therapy. Conclusions This small retrospective study indicates that combination therapy with clindamycin and rifampicin may be effective for HS. However, there is a need for a placebo-controlled trial. Accepted for publication 21 October 2005 | 
|
